WE'LL
KEEP THE
DOSE ON
A DOSE OF CONFIDENCE GOES A LONG WAY.
Once you're back to caring for patients, they'll appreciate that one
DEXTENZA insert gives them their post-op ophthalmic steroid dose,
completely hands-free.
1,2
DEXTENZA is designed to:
• Allow for physician-controlled administration
1
• Provide preservative-free, sustained coverage for up to 30 days
2
INDICATION
DEXTENZA is a corticosteroid indicated for the treatment of
ocular inflammation and pain following ophthalmic surgery.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
DEXTENZA is contraindicated in patients with active corneal,
conjunctival or canalicular infections, including epithelial
herpes simplex keratitis (dendritic keratitis), vaccinia, varicella;
mycobacterial infections; fungal diseases of the eye, and
dacryocystitis.
WARNINGS AND PRECAUTIONS
Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields
of vision. Steroids should be used with caution in the presence
of glaucoma. Intraocular pressure should be monitored during
treatment.
Corticosteroids may suppress the host response and thus
increase the hazard for secondary ocular infections. In acute
purulent conditions, steroids may mask infection and enhance
existing infection.
Use of ocular steroids may prolong the course and may
exacerbate the severity of many viral infections of the eye
(including herpes simplex).
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
culture should be taken when appropriate.
Use of steroids after cataract surgery may delay healing and
increase the incidence of bleb formation.
ADVERSE REACTIONS
The most common ocular adverse reactions that
occurred in patients treated with DEXTENZA were: anterior
chamber inflammation including iritis and iridocyclitis (10%);
intraocular pressure increased (6%); visual acuity reduced (2%);
cystoid macular edema (1%); corneal edema (1%); eye pain
(1%) and conjunctival hyperemia (1%).
The most common non-ocular adverse reaction that occurred in
patients treated with DEXTENZA was headache (1%).
Please see brief summary of full Prescribing Information on
adjacent page.
References: 1. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through
hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 2. DEXTENZA [package insert). Bedford. MA: Ocular
Therapeutlx, Inc: 2019.
© 2020 Ocular Therapeutix, Inc. All rights reserved.
DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0230
